View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsEnzo Biochem 将来の成長Future 基準チェック /06現在、 Enzo Biochemの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長17.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • May 10Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027Enzo Biochem, Inc. provided earnings guidance for the years 2023, 2024, 2025, 2026 and 2027. For the year 2023, the company expects revenue of $52.0 million and LBIT of $15.8 million. For the year 2024, the company expects revenue of $70.4 million and LBIT of $14.4 million. For the year 2025, the company expects revenue of $80.9 million and LBIT of $11.5 million. For the year 2026, the company expects revenue of $94.4 million and LBIT of $6.8 million. For the year 2027, the company expects revenue of $112.7 million and EBIT of $2.6 million.すべての更新を表示Recent updatesお知らせ • Aug 21Enzo Biochem, Inc. Files Form 15Enzo Biochem, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.01 per share.お知らせ • Aug 20Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB).Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. As of August 19 2025, the transaction was approved by target shareholders. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P. Equiniti Trust Company, LLC acted as Transfer agent to Enzo Biochem. Kingsdale Advisors LP acted as a proxy solicitor to Enzo Biochem. Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB) on August 20, 2025.お知らせ • Jun 26Enzo Biochem to Delist After Merger CompletionEnzo Biochem announced that on June 23, following the market close, it entered into an Agreement and Plan of Merger to be acquired by Battery Ventures, a technology-focused investment firm, through its newly formed entity Bethpage Parent. Under the terms of the merger agreement, Battery will acquire Enzo for 70c per share in cash, representing a total consideration of approximately $37 million. Following the closing of the transaction, the company will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges.お知らせ • Jun 25Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million.Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P.Reported Earnings • Mar 18Second quarter 2025 earnings released: US$0.024 loss per share (vs US$0.017 loss in 2Q 2024)Second quarter 2025 results: US$0.024 loss per share (further deteriorated from US$0.017 loss in 2Q 2024). Revenue: US$7.33m (down 14% from 2Q 2024). Net loss: US$1.25m (loss widened 45% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.分析記事 • Feb 13Enzo Biochem, Inc.'s (NYSE:ENZ) 28% Share Price Plunge Could Signal Some RiskTo the annoyance of some shareholders, Enzo Biochem, Inc. ( NYSE:ENZ ) shares are down a considerable 28% in the last...お知らせ • Jan 16Enzo Biochem Receives Non-Compliance Letter from NYSEOn January 8, 2025 Enzo Biochem, Inc. (the Company") received a letter from the New York Stock Exchange (the NYSE") notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because as of January 7, 2025, the Company's 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's Common Stock (the Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder's equity deficiencies and a period of six months to cure the average closing stock price deficiency. The notice does not result in the immediate delisting of the Common Stock from the NYSE. With regards to the average closing stock price deficiency, the Company can regain compliance at any time within the six-month period following receipt of the NYSE's non-compliance notice if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE's listing rules, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and the price remains above that level for at least the following 30 consecutive trading days. The Company will notify the NYSE by January 23, 2025, that it intends to submit a plan by February 21, 2025, to cure the market capitalization, stockholder's equity and average closing stock price deficiencies and to return to compliance with the NYSE's continued listing standards. The Company intends to consider all available alternatives to cure the deficiencies identified by the NYSE. The Common Stock will continue to be listed and trade on the NYSE, subject to the Company's ongoing compliance with the NYSE's other continued listing standards.分析記事 • Dec 18Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some RiskThe Enzo Biochem, Inc. ( NYSE:ENZ ) share price has fared very poorly over the last month, falling by a substantial...Reported Earnings • Dec 17First quarter 2025 earnings released: US$0.059 loss per share (vs US$0.11 loss in 1Q 2024)First quarter 2025 results: US$0.059 loss per share (improved from US$0.11 loss in 1Q 2024). Revenue: US$6.21m (down 20% from 1Q 2024). Net loss: US$3.07m (loss narrowed 46% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.Board Change • Dec 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Brad Radoff is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 28+ 1 more updateEnzo Biochem, Inc., Annual General Meeting, Jan 15, 2025Enzo Biochem, Inc., Annual General Meeting, Jan 15, 2025.分析記事 • Nov 19Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 35% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Shareholders have been diluted in the past year (5.1% increase in shares outstanding). Market cap is less than US$100m (US$60.1m market cap).Reported Earnings • Oct 30Full year 2024 earnings released: US$0.19 loss per share (vs US$0.51 loss in FY 2023)Full year 2024 results: US$0.19 loss per share (improved from US$0.51 loss in FY 2023). Revenue: US$31.9m (up 2.7% from FY 2023). Net loss: US$9.82m (loss narrowed 61% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Oct 30Enzo Biochem, Inc. Announces Cash Dividend, Payable on December 2, 2024The Board of Directors of Enzo Biochem, Inc. has declared a cash dividend of $0.10 per share on its common stock, payable on December 2, 2024, to the holders of record as of the close of business on November 15, 2024.Board Change • Sep 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Brad Radoff is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Jul 17Enzo Biochem: Is This Time Finally Different?Summary Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks. Read the full article on Seeking AlphaReported Earnings • Jun 16Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)Third quarter 2024 results: US$0.042 loss per share (improved from US$0.31 loss in 3Q 2023). Revenue: US$8.02m (down 50% from 3Q 2023). Net loss: US$2.13m (loss narrowed 86% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 14Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.059 loss in 2Q 2023)Second quarter 2024 results: US$0.017 loss per share (improved from US$0.059 loss in 2Q 2023). Revenue: US$8.55m (up 14% from 2Q 2023). Net loss: US$863.0k (loss narrowed 70% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.お知らせ • Feb 01+ 1 more updateEnzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive OfficerOn January 31, 2024, the board of directors of Enzo Biochem, Inc. appointed Kara Cannon to serve as the Chief Executive Officer of the Company, in each case, until her successor is duly elected and qualified. Ms. Cannon previously served as the Company’s interim Chief Executive Officer since her appointment to such position on September 5, 2023, as disclosed in a Current Report on Form 8-K filed by the Company on September 7, 2023. Prior to that, Ms. Cannon was the Company’s Chief Operating Officer; she has been employed with the Company since 2011.お知らせ • Dec 23Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024, at 09:00 US Eastern Standard Time.お知らせ • Nov 01Enzo Biochem, Inc. announced delayed annual 10-K filingOn 10/31/2023, Enzo Biochem, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 31Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of DirectorsEnzo Biochem, Inc. announced that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well. Mr. Pully is currently a partner of Speyside Partners, an investment banking firm that he co-founded in May 2017. He also serves on the boards or in executive positions for various companies, including publicly-traded RumbleOn, Inc., where he serves as the Executive Chairman. Mr. Pully’s board service has spanned multiple industries, including airlines, amusement parks, energy and power, manufacturing, power sports, retail, restaurants, and technology. His board service has included multiple positions as chairman or lead director of the board, and also multiple chairmanships of audit, compensation, nominating and governance, and special committees. Previously, Mr. Pully served as General Counsel and as a Partner of the investment firm, Carlson Capital, L.P. from 2008 to 2014, as Managing Director in the investment banking division of Bank of America and as a Senior Managing Director in the investment banking department of Bear Stearns & Company. Mr. Pully is also an attorney and CPA, he is a Chartered Financial Analyst, and he also holds various FINRA licenses.Seeking Alpha • Oct 26Enzo Biochem: Cleaned Up And Cash-Rich But UnlovedSummary Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares. Enzo's focus on generating positive cash flow and enhancing shareholder value could lead to significant improvement in Life Sciences results. At $1.33 it is nearly a penny stock, but trades below cash and simultaneously, you get the entire $28m+ Life Sciences business for free. Given Labcorp settled their ransomware lawsuit for $2-$4m, it is likely that ENZ’s case will be settled for a similar or smaller sum (a tiny amount relative to ~$80M cash). Read the full article on Seeking AlphaBoard Change • Sep 09High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 07Enzo Biochem, Inc. Announces CEO ChangesEnzo Biochem, Inc. announced that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of thousands of high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo Biochem, Inc.’s Life Science division supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry.分析記事 • May 18Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • May 10Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027Enzo Biochem, Inc. provided earnings guidance for the years 2023, 2024, 2025, 2026 and 2027. For the year 2023, the company expects revenue of $52.0 million and LBIT of $15.8 million. For the year 2024, the company expects revenue of $70.4 million and LBIT of $14.4 million. For the year 2025, the company expects revenue of $80.9 million and LBIT of $11.5 million. For the year 2026, the company expects revenue of $94.4 million and LBIT of $6.8 million. For the year 2027, the company expects revenue of $112.7 million and EBIT of $2.6 million.Reported Earnings • Mar 22Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)Second quarter 2023 results: US$0.23 loss per share (further deteriorated from US$0.055 loss in 2Q 2022). Revenue: US$16.3m (down 52% from 2Q 2022). Net loss: US$11.3m (loss widened 326% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 7% per year.分析記事 • Jan 03Is Enzo Biochem (NYSE:ENZ) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Dec 13First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)First quarter 2023 results: US$0.22 loss per share (further deteriorated from US$0.048 loss in 1Q 2022). Revenue: US$18.3m (down 31% from 1Q 2022). Net loss: US$10.6m (loss widened 359% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.Seeking Alpha • Dec 12Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28MEnzo Biochem press release (NYSE:ENZ): Q1 Non-GAAP EPS of -$0.18. Revenue of $18.28M (-31.1% Y/Y).Recent Insider Transactions • Nov 29CEO & Director recently bought US$197k worth of stockOn the 23rd of November, Hamid Erfanian bought around 100k shares on-market at roughly US$1.97 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth US$5.0m. Hamid has been a buyer over the last 12 months, purchasing a net total of US$207k worth in shares.Recent Insider Transactions • Nov 25Insider recently bought US$5.0m worth of stockOn the 18th of November, James Wolf bought around 662k shares on-market at roughly US$7.50 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$8.0m more in shares than they have sold in the last 12 months.Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 09Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023.Seeking Alpha • Oct 20Enzo Biochem appoints Patricia Eckert as interim CFOEnzo Biochem (NYSE:ENZ) appoints Patricia Eckert as interim CFO, succeeding David Bench, who is departing the company effective November 14, 2022 to pursue a new opportunity. Prior to her nearly five years in various finance roles with Enzo, Ms. Eckert served as accounting director at Pall Corporation.Reported Earnings • Oct 16Full year 2022 earnings releasedFull year 2022 results: Net income: (down US$7.88m from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Seeking Alpha • Oct 14Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28MEnzo Biochem press release (NYSE:ENZ): Q4 Non-GAAP EPS of -$0.17. Revenue of $20.28M (-18.2% Y/Y).分析記事 • Oct 04Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Recent Insider Transactions • Jul 08Independent Director recently bought US$264k worth of stockOn the 5th of July, Bradley Radoff bought around 120k shares on-market at roughly US$2.20 per share. In the last 3 months, they made an even bigger purchase worth US$276k. Insiders have collectively bought US$7.0m more in shares than they have sold in the last 12 months.Seeking Alpha • Jun 27Enzo Biochem: Activist Pressure Could Finally Lead To A Company SaleOn June 9, Enzo Biochem announced a new strategic review that may finally lead to the sale of the long-mismanaged company. Since late 2021, positive changes have taken place - long-time CEO Rabbani was replaced with an independent CEO, an experienced activist was appointed to the Board and Rabbani-affiliated President resigned. For these reasons, a company or asset sale may eventually materialise. The set-up appears to exist because of low liquidity and analyst coverage. Downside is limited by undervaluation and net cash position of ENZ.Recent Insider Transactions • Jun 18Independent Director recently bought US$276k worth of stockOn the 16th of June, Bradley Radoff bought around 125k shares on-market at roughly US$2.20 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$6.7m more in shares than they have sold in the last 12 months.Reported Earnings • Jun 10Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)Third quarter 2022 results: US$0.10 loss per share (down from US$0.041 profit in 3Q 2021). Revenue: US$26.2m (down 20% from 3Q 2021). Net loss: US$4.85m (down 342% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.分析記事 • May 03Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 16Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$0.055 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$34.0m (up 8.2% from 2Q 2021). Net loss: US$2.66m (down 215% from profit in 2Q 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 413%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Board Change • Feb 03High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder, Independent Outside Director & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 08Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Co-Founder, Chairman, Chief Scientific Officer & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. Lead Independent Director Mary Tagliaferri was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Recent Insider Transactions • Dec 30Insider recently bought US$2.5m worth of stockOn the 21st of December, Bradley Radoff bought around 683k shares on-market at roughly US$3.64 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$6.5m more in shares than they have sold in the last 12 months.分析記事 • Dec 17Is Enzo Biochem (NYSE:ENZ) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Dec 17First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: US$0.048 loss per share (down from US$0.006 profit in 1Q 2021). Revenue: US$26.5m (down 7.5% from 1Q 2021). Net loss: US$2.32m (down US$2.62m from profit in 1Q 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 413%. Earnings per share (EPS) missed analyst estimates by 413%. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Oct 24Insider recently bought US$1.5m worth of stockOn the 21st of October, Bradley Radoff bought around 415k shares on-market at roughly US$3.60 per share. In the last 3 months, they made an even bigger purchase worth US$2.5m. Insiders have collectively bought US$4.0m more in shares than they have sold in the last 12 months.Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$3.25, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 22x in the Healthcare industry in the US. Total returns to shareholders of 4.8% over the past three years.Reported Earnings • Oct 13Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$117.7m (up 55% from FY 2020). Net income: US$7.88m (up US$36.4m from FY 2020). Profit margin: 6.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Oct 08Insider recently bought US$2.5m worth of stockOn the 5th of October, Bradley Radoff bought around 721k shares on-market at roughly US$3.42 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$2.6m more in shares than they have sold in the last 12 months.分析記事 • Aug 24Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Jun 12Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$32.8m (up 94% from 3Q 2020). Net income: US$2.01m (up US$11.9m from 3Q 2020). Profit margin: 6.1% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 17Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$31.5m (up 62% from 2Q 2020). Net income: US$2.30m (up US$9.99m from 2Q 2020). Profit margin: 7.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.分析記事 • Mar 01Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Feb 05New 90-day high: US$3.25The company is up 66% from its price of US$1.96 on 06 November 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 3.0% over the same period.分析記事 • Feb 03Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?If you want to know who really controls Enzo Biochem, Inc. ( NYSE:ENZ ), then you'll have to look at the makeup of its...分析記事 • Jan 08If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%While it may not be enough for some shareholders, we think it is good to see the Enzo Biochem, Inc. ( NYSE:ENZ ) share...Is New 90 Day High Low • Jan 05New 90-day high: US$2.66The company is up 22% from its price of US$2.18 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 12% over the same period.分析記事 • Dec 13Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO PayThis article will reflect on the compensation paid to Elazar Rabbani who has served as CEO of Enzo Biochem, Inc...Reported Earnings • Dec 12First quarter 2021 earnings released: EPS US$0.006The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$28.7m (up 42% from 1Q 2020). Net income: US$299.0k (up US$7.95m from 1Q 2020). Profit margin: 1.0% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Enzo Biochem は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ENZB - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数4/30/202527-8-16-15N/A1/31/202529-8-16-15N/A10/31/202430-7-23-22N/A7/31/202432-10-27-26N/A4/30/202433-18-43-42N/A1/31/202433-23-46-44N/A10/31/202332-25-44-42N/A7/31/202331-25-40-37N/A4/30/2023-32-27-32-29N/A1/31/2023-13-24-28-25N/A10/31/202213-23-22-19N/A7/31/202233-20-20-17N/A4/30/2022112-7-12-7N/A1/31/20221180-10-4N/A10/31/20211165-9-4N/A7/31/20211188-40N/A4/30/20211121-9-5N/A1/31/202197-11-14-11N/A10/31/202084-21-19-16N/A7/31/202076-29-19-17N/A4/30/202077-31-17-15N/A1/31/20208021012N/A10/31/201980119N/A7/31/2019812-35N/A4/30/2019832-26N/A1/31/201989-23N/A-18N/A10/31/201895-16N/A-12N/A7/31/2018101-10N/A-3N/A4/30/2018106-4N/A1N/A1/31/2018108-2N/A3N/A10/31/2017108-2N/A3N/A7/31/2017105-3N/A0N/A4/30/201710634N/A34N/A1/31/201710631N/A30N/A10/31/201610439N/A40N/A7/31/201610345N/A53N/A4/30/201610218N/A21N/A1/31/20169917N/A23N/A10/31/2015986N/A12N/A7/31/201598-2N/A-4N/A4/30/201597-14N/A-7N/A1/31/201597-11N/A-3N/A10/31/201497-11N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ENZBの予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ENZBの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ENZBの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ENZBの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ENZBの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ENZBの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/19 01:36終値2025/08/19 00:00収益2025/04/30年間収益2024/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Enzo Biochem, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Bradley BerningCraig-Hallum Capital Group LLCJack WallaceSidoti & Company, LLC
お知らせ • May 10Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027Enzo Biochem, Inc. provided earnings guidance for the years 2023, 2024, 2025, 2026 and 2027. For the year 2023, the company expects revenue of $52.0 million and LBIT of $15.8 million. For the year 2024, the company expects revenue of $70.4 million and LBIT of $14.4 million. For the year 2025, the company expects revenue of $80.9 million and LBIT of $11.5 million. For the year 2026, the company expects revenue of $94.4 million and LBIT of $6.8 million. For the year 2027, the company expects revenue of $112.7 million and EBIT of $2.6 million.
お知らせ • Aug 21Enzo Biochem, Inc. Files Form 15Enzo Biochem, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.01 per share.
お知らせ • Aug 20Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB).Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. As of August 19 2025, the transaction was approved by target shareholders. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P. Equiniti Trust Company, LLC acted as Transfer agent to Enzo Biochem. Kingsdale Advisors LP acted as a proxy solicitor to Enzo Biochem. Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB) on August 20, 2025.
お知らせ • Jun 26Enzo Biochem to Delist After Merger CompletionEnzo Biochem announced that on June 23, following the market close, it entered into an Agreement and Plan of Merger to be acquired by Battery Ventures, a technology-focused investment firm, through its newly formed entity Bethpage Parent. Under the terms of the merger agreement, Battery will acquire Enzo for 70c per share in cash, representing a total consideration of approximately $37 million. Following the closing of the transaction, the company will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges.
お知らせ • Jun 25Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million.Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P.
Reported Earnings • Mar 18Second quarter 2025 earnings released: US$0.024 loss per share (vs US$0.017 loss in 2Q 2024)Second quarter 2025 results: US$0.024 loss per share (further deteriorated from US$0.017 loss in 2Q 2024). Revenue: US$7.33m (down 14% from 2Q 2024). Net loss: US$1.25m (loss widened 45% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
分析記事 • Feb 13Enzo Biochem, Inc.'s (NYSE:ENZ) 28% Share Price Plunge Could Signal Some RiskTo the annoyance of some shareholders, Enzo Biochem, Inc. ( NYSE:ENZ ) shares are down a considerable 28% in the last...
お知らせ • Jan 16Enzo Biochem Receives Non-Compliance Letter from NYSEOn January 8, 2025 Enzo Biochem, Inc. (the Company") received a letter from the New York Stock Exchange (the NYSE") notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because as of January 7, 2025, the Company's 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's Common Stock (the Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder's equity deficiencies and a period of six months to cure the average closing stock price deficiency. The notice does not result in the immediate delisting of the Common Stock from the NYSE. With regards to the average closing stock price deficiency, the Company can regain compliance at any time within the six-month period following receipt of the NYSE's non-compliance notice if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE's listing rules, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and the price remains above that level for at least the following 30 consecutive trading days. The Company will notify the NYSE by January 23, 2025, that it intends to submit a plan by February 21, 2025, to cure the market capitalization, stockholder's equity and average closing stock price deficiencies and to return to compliance with the NYSE's continued listing standards. The Company intends to consider all available alternatives to cure the deficiencies identified by the NYSE. The Common Stock will continue to be listed and trade on the NYSE, subject to the Company's ongoing compliance with the NYSE's other continued listing standards.
分析記事 • Dec 18Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some RiskThe Enzo Biochem, Inc. ( NYSE:ENZ ) share price has fared very poorly over the last month, falling by a substantial...
Reported Earnings • Dec 17First quarter 2025 earnings released: US$0.059 loss per share (vs US$0.11 loss in 1Q 2024)First quarter 2025 results: US$0.059 loss per share (improved from US$0.11 loss in 1Q 2024). Revenue: US$6.21m (down 20% from 1Q 2024). Net loss: US$3.07m (loss narrowed 46% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
Board Change • Dec 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Brad Radoff is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 28+ 1 more updateEnzo Biochem, Inc., Annual General Meeting, Jan 15, 2025Enzo Biochem, Inc., Annual General Meeting, Jan 15, 2025.
分析記事 • Nov 19Will Enzo Biochem (NYSE:ENZ) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 35% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Shareholders have been diluted in the past year (5.1% increase in shares outstanding). Market cap is less than US$100m (US$60.1m market cap).
Reported Earnings • Oct 30Full year 2024 earnings released: US$0.19 loss per share (vs US$0.51 loss in FY 2023)Full year 2024 results: US$0.19 loss per share (improved from US$0.51 loss in FY 2023). Revenue: US$31.9m (up 2.7% from FY 2023). Net loss: US$9.82m (loss narrowed 61% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 30Enzo Biochem, Inc. Announces Cash Dividend, Payable on December 2, 2024The Board of Directors of Enzo Biochem, Inc. has declared a cash dividend of $0.10 per share on its common stock, payable on December 2, 2024, to the holders of record as of the close of business on November 15, 2024.
Board Change • Sep 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Brad Radoff is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Jul 17Enzo Biochem: Is This Time Finally Different?Summary Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks. Read the full article on Seeking Alpha
Reported Earnings • Jun 16Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)Third quarter 2024 results: US$0.042 loss per share (improved from US$0.31 loss in 3Q 2023). Revenue: US$8.02m (down 50% from 3Q 2023). Net loss: US$2.13m (loss narrowed 86% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 14Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.059 loss in 2Q 2023)Second quarter 2024 results: US$0.017 loss per share (improved from US$0.059 loss in 2Q 2023). Revenue: US$8.55m (up 14% from 2Q 2023). Net loss: US$863.0k (loss narrowed 70% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 01+ 1 more updateEnzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive OfficerOn January 31, 2024, the board of directors of Enzo Biochem, Inc. appointed Kara Cannon to serve as the Chief Executive Officer of the Company, in each case, until her successor is duly elected and qualified. Ms. Cannon previously served as the Company’s interim Chief Executive Officer since her appointment to such position on September 5, 2023, as disclosed in a Current Report on Form 8-K filed by the Company on September 7, 2023. Prior to that, Ms. Cannon was the Company’s Chief Operating Officer; she has been employed with the Company since 2011.
お知らせ • Dec 23Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024, at 09:00 US Eastern Standard Time.
お知らせ • Nov 01Enzo Biochem, Inc. announced delayed annual 10-K filingOn 10/31/2023, Enzo Biochem, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 31Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of DirectorsEnzo Biochem, Inc. announced that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well. Mr. Pully is currently a partner of Speyside Partners, an investment banking firm that he co-founded in May 2017. He also serves on the boards or in executive positions for various companies, including publicly-traded RumbleOn, Inc., where he serves as the Executive Chairman. Mr. Pully’s board service has spanned multiple industries, including airlines, amusement parks, energy and power, manufacturing, power sports, retail, restaurants, and technology. His board service has included multiple positions as chairman or lead director of the board, and also multiple chairmanships of audit, compensation, nominating and governance, and special committees. Previously, Mr. Pully served as General Counsel and as a Partner of the investment firm, Carlson Capital, L.P. from 2008 to 2014, as Managing Director in the investment banking division of Bank of America and as a Senior Managing Director in the investment banking department of Bear Stearns & Company. Mr. Pully is also an attorney and CPA, he is a Chartered Financial Analyst, and he also holds various FINRA licenses.
Seeking Alpha • Oct 26Enzo Biochem: Cleaned Up And Cash-Rich But UnlovedSummary Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares. Enzo's focus on generating positive cash flow and enhancing shareholder value could lead to significant improvement in Life Sciences results. At $1.33 it is nearly a penny stock, but trades below cash and simultaneously, you get the entire $28m+ Life Sciences business for free. Given Labcorp settled their ransomware lawsuit for $2-$4m, it is likely that ENZ’s case will be settled for a similar or smaller sum (a tiny amount relative to ~$80M cash). Read the full article on Seeking Alpha
Board Change • Sep 09High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 07Enzo Biochem, Inc. Announces CEO ChangesEnzo Biochem, Inc. announced that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of thousands of high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo Biochem, Inc.’s Life Science division supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry.
分析記事 • May 18Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • May 10Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027Enzo Biochem, Inc. provided earnings guidance for the years 2023, 2024, 2025, 2026 and 2027. For the year 2023, the company expects revenue of $52.0 million and LBIT of $15.8 million. For the year 2024, the company expects revenue of $70.4 million and LBIT of $14.4 million. For the year 2025, the company expects revenue of $80.9 million and LBIT of $11.5 million. For the year 2026, the company expects revenue of $94.4 million and LBIT of $6.8 million. For the year 2027, the company expects revenue of $112.7 million and EBIT of $2.6 million.
Reported Earnings • Mar 22Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)Second quarter 2023 results: US$0.23 loss per share (further deteriorated from US$0.055 loss in 2Q 2022). Revenue: US$16.3m (down 52% from 2Q 2022). Net loss: US$11.3m (loss widened 326% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 7% per year.
分析記事 • Jan 03Is Enzo Biochem (NYSE:ENZ) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Dec 13First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)First quarter 2023 results: US$0.22 loss per share (further deteriorated from US$0.048 loss in 1Q 2022). Revenue: US$18.3m (down 31% from 1Q 2022). Net loss: US$10.6m (loss widened 359% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.
Seeking Alpha • Dec 12Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28MEnzo Biochem press release (NYSE:ENZ): Q1 Non-GAAP EPS of -$0.18. Revenue of $18.28M (-31.1% Y/Y).
Recent Insider Transactions • Nov 29CEO & Director recently bought US$197k worth of stockOn the 23rd of November, Hamid Erfanian bought around 100k shares on-market at roughly US$1.97 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth US$5.0m. Hamid has been a buyer over the last 12 months, purchasing a net total of US$207k worth in shares.
Recent Insider Transactions • Nov 25Insider recently bought US$5.0m worth of stockOn the 18th of November, James Wolf bought around 662k shares on-market at roughly US$7.50 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$8.0m more in shares than they have sold in the last 12 months.
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 09Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023.
Seeking Alpha • Oct 20Enzo Biochem appoints Patricia Eckert as interim CFOEnzo Biochem (NYSE:ENZ) appoints Patricia Eckert as interim CFO, succeeding David Bench, who is departing the company effective November 14, 2022 to pursue a new opportunity. Prior to her nearly five years in various finance roles with Enzo, Ms. Eckert served as accounting director at Pall Corporation.
Reported Earnings • Oct 16Full year 2022 earnings releasedFull year 2022 results: Net income: (down US$7.88m from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Seeking Alpha • Oct 14Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28MEnzo Biochem press release (NYSE:ENZ): Q4 Non-GAAP EPS of -$0.17. Revenue of $20.28M (-18.2% Y/Y).
分析記事 • Oct 04Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Recent Insider Transactions • Jul 08Independent Director recently bought US$264k worth of stockOn the 5th of July, Bradley Radoff bought around 120k shares on-market at roughly US$2.20 per share. In the last 3 months, they made an even bigger purchase worth US$276k. Insiders have collectively bought US$7.0m more in shares than they have sold in the last 12 months.
Seeking Alpha • Jun 27Enzo Biochem: Activist Pressure Could Finally Lead To A Company SaleOn June 9, Enzo Biochem announced a new strategic review that may finally lead to the sale of the long-mismanaged company. Since late 2021, positive changes have taken place - long-time CEO Rabbani was replaced with an independent CEO, an experienced activist was appointed to the Board and Rabbani-affiliated President resigned. For these reasons, a company or asset sale may eventually materialise. The set-up appears to exist because of low liquidity and analyst coverage. Downside is limited by undervaluation and net cash position of ENZ.
Recent Insider Transactions • Jun 18Independent Director recently bought US$276k worth of stockOn the 16th of June, Bradley Radoff bought around 125k shares on-market at roughly US$2.20 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$6.7m more in shares than they have sold in the last 12 months.
Reported Earnings • Jun 10Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)Third quarter 2022 results: US$0.10 loss per share (down from US$0.041 profit in 3Q 2021). Revenue: US$26.2m (down 20% from 3Q 2021). Net loss: US$4.85m (down 342% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
分析記事 • May 03Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 16Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$0.055 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$34.0m (up 8.2% from 2Q 2021). Net loss: US$2.66m (down 215% from profit in 2Q 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 413%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Board Change • Feb 03High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder, Independent Outside Director & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 08Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Co-Founder, Chairman, Chief Scientific Officer & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. Lead Independent Director Mary Tagliaferri was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Recent Insider Transactions • Dec 30Insider recently bought US$2.5m worth of stockOn the 21st of December, Bradley Radoff bought around 683k shares on-market at roughly US$3.64 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$6.5m more in shares than they have sold in the last 12 months.
分析記事 • Dec 17Is Enzo Biochem (NYSE:ENZ) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Dec 17First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: US$0.048 loss per share (down from US$0.006 profit in 1Q 2021). Revenue: US$26.5m (down 7.5% from 1Q 2021). Net loss: US$2.32m (down US$2.62m from profit in 1Q 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 413%. Earnings per share (EPS) missed analyst estimates by 413%. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Oct 24Insider recently bought US$1.5m worth of stockOn the 21st of October, Bradley Radoff bought around 415k shares on-market at roughly US$3.60 per share. In the last 3 months, they made an even bigger purchase worth US$2.5m. Insiders have collectively bought US$4.0m more in shares than they have sold in the last 12 months.
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$3.25, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 22x in the Healthcare industry in the US. Total returns to shareholders of 4.8% over the past three years.
Reported Earnings • Oct 13Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$117.7m (up 55% from FY 2020). Net income: US$7.88m (up US$36.4m from FY 2020). Profit margin: 6.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Oct 08Insider recently bought US$2.5m worth of stockOn the 5th of October, Bradley Radoff bought around 721k shares on-market at roughly US$3.42 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$2.6m more in shares than they have sold in the last 12 months.
分析記事 • Aug 24Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Jun 12Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$32.8m (up 94% from 3Q 2020). Net income: US$2.01m (up US$11.9m from 3Q 2020). Profit margin: 6.1% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 17Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$31.5m (up 62% from 2Q 2020). Net income: US$2.30m (up US$9.99m from 2Q 2020). Profit margin: 7.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
分析記事 • Mar 01Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Feb 05New 90-day high: US$3.25The company is up 66% from its price of US$1.96 on 06 November 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 3.0% over the same period.
分析記事 • Feb 03Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?If you want to know who really controls Enzo Biochem, Inc. ( NYSE:ENZ ), then you'll have to look at the makeup of its...
分析記事 • Jan 08If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%While it may not be enough for some shareholders, we think it is good to see the Enzo Biochem, Inc. ( NYSE:ENZ ) share...
Is New 90 Day High Low • Jan 05New 90-day high: US$2.66The company is up 22% from its price of US$2.18 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 12% over the same period.
分析記事 • Dec 13Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO PayThis article will reflect on the compensation paid to Elazar Rabbani who has served as CEO of Enzo Biochem, Inc...
Reported Earnings • Dec 12First quarter 2021 earnings released: EPS US$0.006The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$28.7m (up 42% from 1Q 2020). Net income: US$299.0k (up US$7.95m from 1Q 2020). Profit margin: 1.0% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.